Fredag 27 December | 00:37:27 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-08-28 07:00 Kvartalsrapport 2025-Q2
2025-06-05 N/A Årsstämma
2025-04-10 00:00 Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.
2024-12-15 11:26:29

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 15 December 2024: Reference is made to the rights issue by Circio Holding ASA (the "Company") completed in July 2024 (the "Rights Issue").

Due to substantial interest from existing shareholders and new investors for the ongoing Warrants exercise, the board of directors of the Company has resolved to open for subscription of additional new shares at an issue price of NOK 0.60 (i.e. equal to the Warrant Exercise Price).

A total of 13,864,852 warrants (Nw.: frittstående tegningsretter) (the "Warrants") were issued in connection with the Rights Issue. Each Warrant gives the holder (the "Holder") a right to subscribe for one new share in the Company at an exercise price per share of NOK 0.60 (the "Warrant Exercise Price"). The Warrants must be exercised no later than 16:30 (CET) on 18 December 2024 (the "Warrant Expiry Time").

The Company has been informed that certain holders will not exercise their Warrants, including Atlas Special Opportunities LLC ("Atlas") which holds 6 million Warrants. These Warrants have been made available to the Company for distribution for free to investors who contact the Company indicating their interests in acquiring Warrants and who will exercise them prior to the Warrant Expiry Time (the "Potential Investors"). Any funds raised from the exercise of Warrants will reduce and delay the requirement to draw future tranches from Atlas under the convertible bond financing facility.

In the event Potential Investors are interested in exercising more Warrants than those available for distribution by the Company, the board of directors is contemplating carrying out a private placement by the issuance of up to 4,903,934 additional new shares at an issue price of NOK 0.60 per share to satisfy such additional demand by use of the authorization to increase the share capital granted by the general meeting on 19 June 2024.

Potential Investors interested in exercising Warrants and subscribing for new shares are requested to complete an application form (the "Application Form") attached to this notice. The Application Form must be completed and received by the Company by e-mail at contact@circio.com before 16.00 hours (CET) on 17 December 2024.

The minimum exercise and subscription amount per Potential Investor is NOK 50,000, which corresponds to 83,333 shares. The allocation of Warrants and private placement shares among Potential Investors will be at the sole discretion of the Company.

The Company will on 18 December 2024 contact the Potential Investors who are being allocated Warrants and private placement shares to inform them of the number of Warrants and shares allocated to them and provide information on the allocation and total payment information.